uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Women's and Children's Health. (Barnendokrinologisk forskning/Gustafsson)
Show others and affiliations
2008 (English)In: Multiple Sclerosis, ISSN 1352-4585, Vol. 14, no 5, 679-690 p.Article in journal (Refereed) Published
Abstract [en]

Objective To estimate the cost-effectiveness of a new treatment (natalizumab) for multiple sclerosis ( MS) compared with current standard therapy with disease-modifying drugs (DMDs) in Sweden. Methods A Markov model was constructed to illustrate disease progression based on functional disability ( the Expanded Disability Status Scale (EDSS)). The effectiveness of natalizumab was based on a 2-year clinical trial in 942 patients ( AFFIRM). The effectiveness of current DMDs was estimated from a matched sample of 512 patients in the Stockholm MS registry. Patients withdrawing from treatment were assumed to follow the disease course of 824 patients with relapsing-remitting disease at onset in the Ontario natural history cohort. Costs and utilities are based on a recent observational study in 1339 patients. All data sets were available at the patient level. Main results are presented from the societal perspective, over a 20-year time frame, in 2005 Euros ( is an element of 1 = 9.25 SEK). Results In the base case, treatment with natalizumab was less expensive and more effective than treatment with current DMDs. When only healthcare costs were considered, the cost per quality-adjusted life year gained with natalizumab was is an element of 38 145. Results are sensitive only to the time horizon of the analysis and assumptions about effectiveness of natalizumab beyond the trial. Conclusions This cost-effectiveness analysis used registry data, cohort and observational studies to extrapolate the efficacy findings of natalizumab from the AFFIRM clinical trial to measure effectiveness in clinical practice. The analysis results suggest that for the population considered, natalizumab provides an additional health benefit at a similar cost to current DMDs from a societal perspective.

Place, publisher, year, edition, pages
2008. Vol. 14, no 5, 679-690 p.
Keyword [en]
cost effectiveness, modeling, MS registry, multiple sclerosis, Sweden
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-110036DOI: 10.1177/1352458507086667ISI: 000256882200013PubMedID: 18566030OAI: oai:DiVA.org:uu-110036DiVA: diva2:275058
Available from: 2009-11-03 Created: 2009-11-02 Last updated: 2010-03-31Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
Department of Women's and Children's Health
In the same journal
Multiple Sclerosis
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 151 hits
ReferencesLink to record
Permanent link

Direct link